Company intelligence / Profile preview

Accanis Biotech

Ownership: Private
Development stage: Other

Overview

Accanis Biotech is developing optimized IVT mRNA therapeutics with broad and long-lasting effects, aiming to surpass traditional protein-based therapies. Their lead programs target fibroblast growth factor 2 for disorders of aging and interferon alpha for actinic keratosis. Both are currently in preclinical development; no clinical results have been reported yet.

Therapeutic areas: DermatologyNeurology
Modalities: mRNAPeptide drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Accanis Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accanis Biotech.

Explore the full profile